GLMD.O Surges as New Cancer Treatment Shows Promise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 Nov 25
Source: MarketWatch
Shares of GLMD.O experienced a notable uptick today, crossing above its 5-day simple moving average (SMA), indicating a potential bullish trend. This movement follows the announcement of a promising study that highlights a new combination treatment involving Aramchol, Bayer's Stivarga, and Metformin, which has shown enhanced efficacy against gastrointestinal cancers. The company is set to file new patents to protect this innovative treatment strategy, coinciding with the expiration of existing patents for Stivarga between 2028 and 2032. With Phase 1b clinical trials anticipated to commence in early 2026, investor interest in Galmed Pharmaceuticals is likely to grow, as the firm aims to address significant unmet medical needs in oncology.
Analyst Views on GLMD
About GLMD
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
